군발두통 시장 : 전략적 인사이트와 예측(2026-2035년)

The Cluster Headache Market is expected to grow from USD 6.38 billion in 2026 at a 5.2% CAGR to USD 10.05 billion in 2035.

Rising awareness among healthcare professionals, improvements in diagnostic pathways, and increasing investment in rare neurological disorders are supporting market expansion while creating new opportunities for pharmaceutical companies, biotechnology firms, and medical device manufacturers.

Cluster headache is a rare but highly debilitating neurological disorder characterized by recurrent attacks of severe unilateral pain accompanied by cranial autonomic symptoms such as lacrimation, nasal congestion, conjunctival injection, and eyelid edema. The disease is classified into episodic and chronic forms, with episodic cluster headache accounting for the majority of diagnosed cases. Although oxygen therapy and triptans remain the cornerstone of acute management, recent advances in preventive therapies and targeted biologics are transforming the treatment landscape.

Market Drivers

Rising Disease Awareness and Improved Diagnosis

Growing awareness among neurologists, primary care physicians, and patient advocacy organizations has significantly improved recognition of cluster headache. Updated diagnostic guidelines and increasing referrals to specialist headache clinics are enabling earlier diagnosis and timely treatment initiation.

Expansion of Preventive Therapies

Healthcare providers are increasingly emphasizing preventive treatment strategies to reduce attack frequency and improve long-term quality of life. The growing use of CGRP monoclonal antibodies and optimized preventive regimens is supporting sustained market growth.

Increasing Adoption of Neuromodulation Technologies

Non-invasive vagus nerve stimulation and other neuromodulation devices are emerging as valuable treatment options for patients who experience inadequate response to conventional pharmacological therapies. Continued technological innovation is expanding therapeutic options and improving patient outcomes.

Growing Investment in Rare Neurological Disorders

Supportive orphan drug regulations, increasing neuroscience research, and expanding pharmaceutical investment are accelerating development of innovative therapies for cluster headache, strengthening future market growth.

Market Restraints

Limited Patient Population

Cluster headache remains a relatively rare disorder, reducing the available patient pool for clinical research and limiting commercial opportunities compared with more prevalent neurological diseases.

Delayed Diagnosis

Despite improved awareness, many patients continue to experience delayed or incorrect diagnosis because symptoms may be confused with migraine, sinus disorders, or other headache conditions.

High Cost of Innovative Therapies

Biologic therapies and advanced neuromodulation devices often carry premium prices, creating reimbursement challenges and limiting patient access in several healthcare systems.

Market and Technology Insights

The global cluster headache market can be segmented by treatment type, drug class, disease type, route of administration, end user, distribution channel, and geography.

By treatment type, the market includes acute treatment, preventive treatment, and bridge treatment. Acute therapies continue to dominate because rapid pain relief remains essential during attacks, while preventive therapies represent the fastest-growing segment due to increasing emphasis on long-term disease control.

By drug class, the market comprises triptans, CGRP monoclonal antibodies, calcium channel blockers, corticosteroids, lithium, and other supportive therapies. Triptans remain the standard acute treatment, whereas CGRP-targeted therapies are experiencing rapid adoption because of their targeted mechanism and favorable preventive efficacy.

By disease type, the market includes episodic cluster headache and chronic cluster headache. Episodic disease accounts for the largest treatment population, while chronic cluster headache continues to drive demand for innovative therapies because of its persistent disease burden.

By route of administration, therapies include oral, injectable, intranasal, inhalational, and device-based treatments. Injectable triptans and oxygen therapy remain the preferred acute treatment options, while injectable biologics are expanding within preventive care.

By end user, the market covers hospitals, specialty headache clinics, neurology centers, ambulatory care centers, and home care settings. Specialty headache centers are increasingly adopting biologics and neuromodulation technologies for patients requiring advanced disease management.

Technological innovation continues to improve disease management through artificial intelligence-assisted diagnosis, wearable monitoring devices, digital headache diaries, telemedicine platforms, and advanced neuromodulation technologies.

Market Trends

The cluster headache market continues to evolve toward personalized neurological care.

Key trends include:

• Growing adoption of CGRP-targeted biologics.
• Increasing utilization of neuromodulation devices.
• Expansion of specialist headache centers.
• Greater use of digital health technologies.
• Increasing investment in orphan neurological disorders.
• Improved physician awareness and earlier diagnosis.
• Rising focus on chronic cluster headache management.

Regional Insights

North America remains the largest market because of advanced neurological care infrastructure, strong clinical research capabilities, favorable reimbursement systems, and widespread adoption of innovative therapies. The region continues to lead commercialization of biologics and neuromodulation technologies.

Europe maintains a significant market share through comprehensive healthcare systems, structured treatment guidelines, increasing physician awareness, and expanding use of preventive therapies.

Asia-Pacific is expected to register the fastest growth during the forecast period owing to improving healthcare infrastructure, rising neurological disease awareness, expanding specialist services, and increasing pharmaceutical investment across China, Japan, South Korea, India, and Australia.

Latin America and the Middle East & Africa continue to improve diagnosis and treatment through healthcare modernization, physician education, and increasing access to specialist neurology services.

Competitive Landscape

The global cluster headache market consists of multinational pharmaceutical companies, biotechnology firms, medical device manufacturers, and specialty neurology companies.

Industry participants continue investing in CGRP-targeted therapies, neuromodulation technologies, precision medicine, artificial intelligence-assisted drug discovery, and digital healthcare solutions. Strategic licensing agreements, research collaborations, mergers and acquisitions, and orphan drug development programs remain important competitive strategies for strengthening market position.

Future Outlook

The future of the cluster headache market is expected to be driven by continued advances in neuroscience, targeted biologics, precision medicine, and digital health technologies. Increasing use of artificial intelligence, wearable monitoring devices, real-world evidence, and personalized treatment approaches is expected to improve disease management while supporting commercialization of next-generation therapies.

Continued investment in rare neurological disorders and expansion of global clinical research are expected to strengthen innovation and improve long-term patient outcomes through 2035.

Conclusion

The global Cluster Headache Market is expected to experience sustained growth through 2035, supported by increasing diagnosis rates, expanding preventive treatment options, growing adoption of CGRP-targeted biologics, and continuous innovation in neuromodulation technologies. Although challenges related to delayed diagnosis, limited patient populations, and reimbursement remain, advances in precision neurology, digital healthcare, and targeted therapeutics are expected to significantly improve patient outcomes while creating attractive growth opportunities for healthcare stakeholders.

Key Benefits of this Report

• Comprehensive analysis of the global cluster headache market and future growth opportunities.
• Detailed evaluation of treatment trends, therapeutic innovations, and market dynamics.
• Competitive assessment of leading companies, pipeline developments, and strategic initiatives.
• Insights into regulatory developments, reimbursement trends, and commercialization opportunities.
• Valuable resource for pharmaceutical companies, biotechnology firms, medical device manufacturers, healthcare providers, researchers, investors, consultants, and policymakers.

What Businesses Use Our Reports For

Market forecasting, competitive intelligence, portfolio optimization, licensing and partnership evaluation, commercialization planning, regulatory strategy development, investment analysis, clinical development planning, and identification of emerging business opportunities.

Report Coverage

• Historical data from 2021 to 2024, Base Year 2025, and Forecast Period 2026 to 2035
• Comprehensive analysis of the global cluster headache market by treatment type, drug class, disease type, route of administration, end user, distribution channel, and geography
• Evaluation of market size, growth drivers, restraints, competitive landscape, treatment trends, and technological advancements
• Assessment of regulatory developments, reimbursement landscape, strategic collaborations, licensing activities, mergers and acquisitions, and commercialization strategies
• Analysis of acute therapies, preventive therapies, CGRP-targeted biologics, neuromodulation technologies, digital health innovations, and future market opportunities through 2035.

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Overview
• 1.2 Key Findings
• 1.3 Cluster Headache Market Snapshot
• 1.4 Key Growth Drivers
• 1.5 Key Challenges
• 1.6 Emerging Opportunities
• 1.7 Analyst Recommendations

2. Disease & Epidemiology Analysis

• 2.1 Overview of Cluster Headache
  • 2.1.1 Definition and Clinical Characteristics
  • 2.1.2 Disease Burden and Unmet Needs
  • 2.1.3 Pathophysiology and Disease Mechanisms
• 2.2 Classification of Cluster Headache
  • 2.2.1 Episodic Cluster Headache
  • 2.2.2 Chronic Cluster Headache
• 2.3 Risk Factors and Disease Triggers
• 2.4 Diagnosis and Patient Journey
  • 2.4.1 Diagnostic Criteria
  • 2.4.2 Differential Diagnosis
  • 2.4.3 Time to Diagnosis and Treatment Challenges
• 2.5 Epidemiology Analysis
  • 2.5.1 Historical and Forecast Patient Population
  • 2.5.2 Prevalence Analysis
  • 2.5.3 Incidence Analysis
  • 2.5.4 Diagnosed Patient Population
  • 2.5.5 Treated Patient Population
  • 2.5.6 Gender-wise Epidemiology
  • 2.5.7 Age-wise Epidemiology
  • 2.5.8 Episodic Cluster Headache Population
  • 2.5.9 Chronic Cluster Headache Population

3. Market Dynamics

• 3.1 Market Drivers
  • 3.1.1 Increasing Disease Awareness
  • 3.1.2 Growing Diagnosis Rates
  • 3.1.3 Availability of Targeted Therapies
  • 3.1.4 Advancements in Neuromodulation Technologies
• 3.2 Market Restraints
  • 3.2.1 Underdiagnosis and Misdiagnosis
  • 3.2.2 Limited Approved Treatment Options
  • 3.2.3 Reimbursement Challenges
• 3.3 Market Opportunities
  • 3.3.1 CGRP-Targeted Therapies
  • 3.3.2 Non-Invasive Neuromodulation
  • 3.3.3 Expansion in Emerging Markets
• 3.4 Market Challenges
• 3.5 Porter's Five Forces Analysis
• 3.6 PESTLE Analysis
• 3.7 Value Chain Analysis

4. Commercial & Market Access

• 4.1 Treatment Adoption Trends
• 4.2 Pricing Analysis
• 4.3 Reimbursement Landscape
• 4.4 Market Access Challenges
• 4.5 Stakeholder Analysis
• 4.6 Healthcare Infrastructure Assessment
• 4.7 Patient Assistance Programs

5. Innovation & Pipeline Landscape

• 5.1 Innovation Overview
• 5.2 Emerging Technologies
  • 5.2.1 CGRP-Based Therapeutics
  • 5.2.2 Neuromodulation Devices
  • 5.2.3 Precision Medicine Approaches
• 5.3 Pipeline Landscape by Development Stage
  • 5.3.1 Phase I Pipeline Candidates
  • 5.3.2 Phase II Pipeline Candidates
  • 5.3.3 Phase III Pipeline Candidates
• 5.4 Pipeline Analysis by Mechanism of Action
• 5.5 Pipeline Analysis by Modality
  • 5.5.1 Monoclonal Antibodies
  • 5.5.2 Small Molecules
  • 5.5.3 Medical Devices
  • 5.5.4 Neuromodulation Technologies
• 5.6 Clinical Trial Landscape
• 5.7 Patent Analysis
• 5.8 Recent Developments and Strategic Activities

6. Treatment Landscape

• 6.1 Current Treatment Algorithm
• 6.2 Acute Treatment Landscape
  • 6.2.1 Oxygen Therapy
  • 6.2.2 Triptans
  • 6.2.3 Other Acute Therapies
• 6.3 Preventive Treatment Landscape
  • 6.3.1 Calcium Channel Blockers
  • 6.3.2 Corticosteroids
  • 6.3.3 CGRP Monoclonal Antibodies
  • 6.3.4 Other Preventive Therapies
• 6.4 Neuromodulation Treatment Landscape
• 6.5 Comparative Assessment of Available Therapies
• 6.6 Unmet Clinical Needs

7. Global Cluster Headache Market Forecast Report Size & Forecast

• 7.1 Market Overview
• 7.2 Historical Market Size Analysis (2021-2025)
• 7.3 Forecast Market Size Analysis (2026-2035)
• 7.4 Absolute Dollar Opportunity Analysis
• 7.5 Market Attractiveness Analysis

8. Global Cluster Headache Market Forecast Report Segmentation

• 8.1 By Treatment Type
  • 8.1.1 Acute Treatment
  • 8.1.2 Preventive Treatment
  • 8.1.3 Bridge Treatment
• 8.2 By Drug Class
  • 8.2.1 Triptans
  • 8.2.2 CGRP Monoclonal Antibodies
  • 8.2.3 Calcium Channel Blockers
  • 8.2.4 Corticosteroids
  • 8.2.5 Others
• 8.3 By Disease Type
  • 8.3.1 Episodic Cluster Headache
  • 8.3.2 Chronic Cluster Headache
• 8.4 By Route of Administration
  • 8.4.1 Injectable
  • 8.4.2 Oral
  • 8.4.3 Intranasal
• 8.5 By End User
  • 8.5.1 Hospitals
  • 8.5.2 Specialty Clinics
  • 8.5.3 Homecare Settings
  • 8.5.4 Others
• 8.6 By Distribution Channel
  • 8.6.1 Hospital Pharmacies
  • 8.6.2 Retail Pharmacies
  • 8.6.3 Online Pharmacies

9. Geographical Analysis

• 9.1 North America
  • 9.1.1 Market Size and Forecast
  • 9.1.2 Demand Drivers
  • 9.1.3 Regional Regulatory Overview
  • 9.1.4 Competitive Intensity
• 9.2 Europe
  • 9.2.1 Market Size and Forecast
  • 9.2.2 Demand Drivers
  • 9.2.3 Regional Regulatory Overview
  • 9.2.4 Competitive Intensity
• 9.3 Asia-Pacific
  • 9.3.1 Market Size and Forecast
  • 9.3.2 Demand Drivers
  • 9.3.3 Regional Regulatory Overview
  • 9.3.4 Competitive Intensity
• 9.4 Latin America
  • 9.4.1 Market Size and Forecast
  • 9.4.2 Demand Drivers
  • 9.4.3 Regional Regulatory Overview
  • 9.4.4 Competitive Intensity
• 9.5 Middle East & Africa
  • 9.5.1 Market Size and Forecast
  • 9.5.2 Demand Drivers
  • 9.5.3 Regional Regulatory Overview
  • 9.5.4 Competitive Intensity

10. Key Countries Analysis

• 10.1 United States
  • 10.1.1 Market Size and Forecast
  • 10.1.2 Epidemiology Analysis
  • 10.1.3 Regulatory Framework
  • 10.1.4 Reimbursement Landscape
  • 10.1.5 Key Companies and Products Presence
• 10.2 Canada
• 10.3 Germany
• 10.4 United Kingdom
• 10.5 France
• 10.6 Italy
• 10.7 Spain
• 10.8 China
• 10.9 Japan
• 10.10 India
• 10.11 South Korea
• 10.12 Australia
• 10.13 Brazil
• 10.14 Mexico
• 10.15 Saudi Arabia
• 10.16 South Africa

11. Regulatory & Policy Landscape

• 11.1 Global Regulatory Overview
• 11.2 United States Regulatory Framework (FDA)
• 11.3 Europe Regulatory Framework (EMA)
• 11.4 Japan Regulatory Framework (PMDA)
• 11.5 India Regulatory Framework (CDSCO)
• 11.6 China Regulatory Framework (NMPA)
• 11.7 Medical Device Regulatory Considerations
• 11.8 Market Authorization Pathways
• 11.9 Reimbursement and Health Technology Assessment Trends

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Competitive Benchmarking
• 12.3 Product Portfolio Assessment
• 12.4 Pipeline Competitiveness Analysis
• 12.5 Strategic Developments
  • 12.5.1 Partnerships and Collaborations
  • 12.5.2 Licensing Agreements
  • 12.5.3 Acquisitions and Mergers
  • 12.5.4 Regulatory Milestones

13. Company Profiles

• 13.1 GlaxoSmithKline plc
  • 13.1.1 Company Overview
  • 13.1.2 Approved Products Relevant to Cluster Headache Management
  • 13.1.3 Key Indications
  • 13.1.4 Verified Pipeline Assets
  • 13.1.5 Strategic Outlook
• 13.2 Medtronic
  • 13.2.1 Company Overview
  • 13.2.2 Neuromodulation Portfolio
  • 13.2.3 Key Indications
  • 13.2.4 Verified Pipeline and Innovation Activities
  • 13.2.5 Strategic Outlook
• 13.3 Eli Lilly and Company
  • 13.3.1 Company Overview
  • 13.3.2 Emgality (galcanezumab)
  • 13.3.3 Key Indications
  • 13.3.4 Verified Pipeline Assets
  • 13.3.5 Strategic Outlook
• 13.4 electroCore, Inc.
  • 13.4.1 Company Overview
  • 13.4.2 gammaCore
  • 13.4.3 Key Indications
  • 13.4.4 Verified Pipeline and Technology Development
  • 13.4.5 Strategic Outlook
• 13.5 Pfizer Inc.
  • 13.5.1 Company Overview
  • 13.5.2 Approved Products Relevant to Headache Management
  • 13.5.3 Key Indications
  • 13.5.4 Verified Pipeline Assets
  • 13.5.5 Strategic Outlook
• 13.6 Grunenthal GmbH
  • 13.6.1 Company Overview
  • 13.6.2 Pain Management Portfolio
  • 13.6.3 Key Indications
  • 13.6.4 Verified Pipeline Assets
  • 13.6.5 Strategic Outlook
• 13.7 Viatris Inc.
  • 13.7.1 Company Overview
  • 13.7.2 Headache and Pain Management Portfolio
  • 13.7.3 Key Indications
  • 13.7.4 Verified Pipeline Assets
  • 13.7.5 Strategic Outlook
• 13.8 Autonomic Technologies Inc.
  • 13.8.1 Company Overview
  • 13.8.2 Cluster Headache Neuromodulation Technology Portfolio
  • 13.8.3 Key Indications
  • 13.8.4 Verified Development Programs
  • 13.8.5 Strategic Outlook
• 13.9 Zosano Pharma Corp.
  • 13.9.1 Company Overview
  • 13.9.2 Migraine and Headache Technology Portfolio
  • 13.9.3 Key Indications
  • 13.9.4 Verified Development Programs
  • 13.9.5 Strategic Outlook
• 13.10 Bausch Health Companies Inc.
  • 13.10.1 Company Overview
  • 13.10.2 Neurology and Pain Management Portfolio
  • 13.10.3 Key Indications
  • 13.10.4 Verified Pipeline Assets
  • 13.10.5 Strategic Outlook

14. Future Outlook

• 14.1 Market Outlook Through 2035
• 14.2 Future Treatment Paradigm
• 14.3 Emerging Technologies Impact
• 14.4 Pipeline Commercialization Outlook
• 14.5 Investment Opportunities
• 14.6 Key Success Factors

15. Methodology

• 15.1 Research Objectives
• 15.2 Study Assumptions
• 15.3 Data Collection Methodology
• 15.4 Epidemiology Modeling Approach
• 15.5 Market Forecasting Methodology
• 15.6 Data Validation and Triangulation
• 15.7 Abbreviations and Definitions
• 15.8 Disclaimer and Scope Limitations